Yazar "Alroughani, R." için listeleme

Toplam kayıt 8, listelenen: 1-8

Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok, A.; Malpas, C.; Horakova, D.; Havrdova, E.; Alroughani, R.; Terzi, M.; Altintas, A. (Sage Publications Ltd, 2018)

…
Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Sharmin, S.; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Lechner-Scott, J. (Sage Publications Ltd, 2019)

…
Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman, T.; Izquierdo, G.; Alroughani, R.; Fernandez Bolaos, R.; Havrdova, E.; Horaova, D.; Butzkueven, H. (Sage Publications Ltd, 2015)

…
Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

Lizak, N.; Lugaresi, A.; Alroughani, R.; Lechner-Scott, J.; Slee, M.; Havrdova, E.; Rio, M. E. (Sage Publications Ltd, 2015)

…
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod [Meeting Abstract]

Fragoso, Y. D.; Alroughani, R.; Barnett, M.; Brooks, J. B.; Butzkueven, H.; Boz, C.; Ticha, V. (Sage Publications Ltd, 2016)

…
MS cohorts and treatment utilization in academic centres in the Middle East

Moradi, N.; Sharmin, S.; Malpas, C.; Ozakbas, S.; Shaygannejad, V.; Alroughani, R.; Kalincik, T. (Sage Publications Ltd, 2019)

…
NMOBase is a Web-based, global observational registry for an 'orphan' disorder: neuromyelitis optica

Kister, I.; Bacon, T.; Alroughani, R.; Boz, C.; Cristiano, E.; Iuliano, G.; Butzkueven, H. (Sage Publications Ltd, 2014)

…
Real-world experience with Ocrelizumab in the MSBase Registry

Butzkueven, H.; Spelman, T.; Patti, F.; Ozakbas, S.; Eichau, S.; Alroughani, R.; Craveiro, L. (Sage Publications Ltd, 2019)

…